



NDA 21652/S-015

SUPPLEMENT APPROVAL

ViiV Healthcare Company
c/o GlaxoSmithKline
Attention: Laura Bacot
U.S. Regulatory Regional Representative, Global Regulatory Affairs
5 Moore Drive, Room 5.5381.5C
P.O. Box 13398
Research Triangle Park, NC 27709-3398

Dear Ms. Bacot:

Please refer to your Supplemental New Drug Application (sNDA) dated February 17, 2012, received February 17, 2012, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for EPZICOM (abacavir sulfate and lamivudine) Tablets.

This "Prior Approval" supplemental new drug application provides for changes in labeling to furnish adequate information for the safe and effective use of Epzicom, as requested in the Division's February 6, 2012 Prior Approval Supplement Request letter.

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert, text for the Medication Guide), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please contact Elizabeth Thompson, M.S., Regulatory Project Manager, at (301) 796-0824 or via email at elizabeth.thompson@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Debra Birnkrant, M.D.
Director
Division of Antiviral Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

KENDALL A MARCUS
03/12/2012